Form 4: Whitehawk Therapeutics Executive Stock Option Grant

David Dornan, Chief Scientific Officer of Whitehawk Therapeutics, Inc., was granted a significant stock option on April 1, 2026.

Summary

• David Dornan, Chief Scientific Officer at Whitehawk Therapeutics, Inc., received a stock option grant on April 1, 2026.
• The option allows for the purchase of 282,340 shares of common stock at an exercise price of $3.54 per share.
• The option has a vesting commencement date of April 1, 2026, and is set to fully vest on the four-year anniversary of this date.
• Vesting occurs in stages: 25% on the one-year anniversary, with the remaining shares vesting monthly over the subsequent three years.
• This grant is subject to Mr. Dornan remaining a Service Provider as defined by the Issuer's 2021 Equity Incentive Plan.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, as it represents a standard executive compensation practice rather than a significant financial event.

Positives

• Significant stock option grant to a key executive (Chief Scientific Officer), indicating potential alignment of executive interests with shareholder value.
• The option's exercise price of $3.54 suggests a potential for future stock price appreciation above this level.
• A structured vesting schedule over four years encourages long-term commitment from the executive.

Negatives

• The grant is contingent on continued employment, meaning forfeiture is possible if the executive departs.
• The exercise price of $3.54 implies that the stock price needs to increase significantly for the option to be profitable.

Risks

• The value of the stock option is entirely dependent on the future performance and stock price of Whitehawk Therapeutics, Inc.
• If the company's stock price does not exceed $3.54 per share, the stock options will likely expire worthless.
• The executive's continued employment is a condition for vesting, introducing a risk of forfeiture if employment is terminated.

Future Outlook

The stock option grant suggests management's belief in the future growth and value appreciation of Whitehawk Therapeutics, Inc., as the executive's compensation is tied to this potential.

Industry Context

StockSavvy.ai notes that stock option grants to senior scientific officers are common in the biotechnology and pharmaceutical sectors, serving as a key incentive for innovation and long-term company success.

Stakeholder Impact

• Shareholders: The grant aligns executive interests with potential stock price appreciation, but also represents potential future dilution if options are exercised.
• Employees: May signal confidence in the company's future, potentially boosting morale.
• Management: Directly benefits from the stock option grant if the company performs well.

Next Steps

• The stock option will vest according to the schedule outlined, provided the reporting person remains a Service Provider.
• The reporting person may exercise the vested options at any time up to the expiration date of April 1, 2036.

Key Dates

Keywords

Form 4, Stock Option, Whitehawk Therapeutics, David Dornan, Executive Compensation, Vesting Schedule, Securities Exchange Act, Insider Trading, Equity Incentive Plan